HER2阻害剤の市場規模、シェア、成長分析、治療別、用途別、エンドユーザー別、地域別 - 産業予測、2025年～2032年

HER2阻害剤の世界市場規模は、2023年に92億米ドルと評価され、予測期間（2025年～2032年）のCAGRは10.2％で成長し、2024年の101億4,000万米ドルから2032年には220億5,000万米ドルに成長する見通しです。

乳がんや胃がん、特にHER2陽性変異体の有病率の上昇が、標的がん治療に不可欠なHER2阻害剤の世界需要を牽引しています。これらの攻撃的ながんは生存率が低いため、患者の予後を改善することを目的とした精密治療が増加しています。免疫組織化学（IHC）や蛍光in situハイブリダイゼーション（FISH）のような診断技術の進歩が早期発見を強化し、HER2阻害剤の使用をさらに高めています。同時に、新しい抗体薬物複合体（ADC）やバイオシミラーの導入により、薬剤費が削減され、重要な治療へのアクセスが拡大しています。米国FDAとEMAによる規制上の支援は、HER2標的治療薬の迅速な承認経路と並んで臨床開発を強化し、HER2阻害剤を腫瘍ポートフォリオにおける焦点として位置づけ、市場成長を促進しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制分析
• 技術分析
• ケーススタディ

HER2阻害剤市場規模：治療別& CAGR（2025年～2032年）

• 市場概要
• 単剤療法
  • シングルエージェント HER2阻害剤
  • HER2標的療法
• 併用療法
  • HER2阻害剤化学療法との併用
  • HER2阻害剤標的療法との併用
  • HER2阻害剤ホルモン療法との併用

HER2阻害剤市場規模：用途別& CAGR（2025年～2032年）

• 市場概要
• 扁平上皮がん
• 腺がん
• 大細胞がん
• 乳がん
• その他の用途

HER2阻害剤市場規模：エンドユーザー別& CAGR（2025年～2032年）

• 市場概要
• 病院
• クリニック
• その他のエンドユーザー

HER2阻害剤市場規模：地域別& CAGR（2025年～2032年）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• Genentech（USA）
• Hoffmann-La Roche（Switzerland）
• Pfizer Inc.（USA）
• AstraZeneca（United Kingdom）
• Novartis AG（Switzerland）
• Amgen Inc.（USA）
• Eli Lilly and Company（USA）
• Biogen Inc.（USA）
• Sanofi S.A.（France）
• Symbio Pharmaceuticals（USA）
• Puma Biotechnology（USA）
• Ipca Laboratories（India）

結論と提言

Global HER2 Inhibitors Market size was valued at USD 9.2 billion in 2023 and is poised to grow from USD 10.14 billion in 2024 to USD 22.05 billion by 2032, growing at a CAGR of 10.2% during the forecast period (2025-2032).

The rising prevalence of breast and gastric cancers, particularly HER2-positive variants, is driving the global demand for HER2 inhibitors, crucial for targeted cancer therapies. These aggressive cancers exhibit lower survival rates, prompting an increase in precision treatments aimed at improving patient outcomes. Advancements in diagnostic technologies such as immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are enhancing early detection, further elevating the use of HER2 inhibitors. Concurrently, the introduction of new antibody-drug conjugates (ADCs) and biosimilars is reducing drug costs and expanding access to vital care. Regulatory support from the U.S. FDA and EMA, alongside expedited approval pathways for HER2-targeted therapies, is bolstering clinical development, positioning HER2 inhibitors as a focal point in oncology portfolios and driving market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global HER2 Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global HER2 Inhibitors Market Segments Analysis

Global HER2 Inhibitors Market is segmented by Treatment, Application, End User and region. Based on Treatment, the market is segmented into Monotherapy and Combination Therapy. Based on Application, the market is segmented into Squamous Cell Carcinoma, Adenocarcinoma, Large Cell Carcinoma, Breast Cancer and Other Applications. Based on End User, the market is segmented into Hospitals, Clinics and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global HER2 Inhibitors Market

The rising incidence of HER2-positive cancers, particularly in breast and gastric cancer cases, significantly drives the growth of the global HER2 inhibitors market. Enhanced education and awareness, alongside advancements in diagnostic capabilities, have led to improved early detection rates, resulting in a larger pool of patients requiring HER2-targeted therapies. This expanding patient demographic is not only increasing the market share for HER2 inhibitors globally but is also fueling the ongoing demand for improved and innovative HER2 inhibitor treatments within healthcare systems worldwide. Consequently, the need for advanced therapies continues to rise, further establishing the significance of this market segment.

Restraints in the Global HER2 Inhibitors Market

The Global HER2 Inhibitors market faces significant constraints primarily due to the high costs associated with these therapies. Although HER2 inhibitors offer substantial clinical benefits, their exorbitant prices severely limit access, especially in low- and middle-income countries. This financial burden affects healthcare systems and patients alike, creating a significant barrier to accessing these potentially life-saving treatments. Consequently, the high treatment costs hinder market growth and impede equitable access to advanced oncological therapies on a global scale. As a result, the potential for widespread adoption and improved patient outcomes remains significantly restricted.

Market Trends of the Global HER2 Inhibitors Market

The global HER2 inhibitors market is witnessing significant growth, propelled by advancements in targeted therapy and the rise of personalized medicine. Innovative HER2 inhibitors are being developed with enhanced specificity and efficacy, tailored specifically for HER2-positive cancers. This evolution not only aims to improve patient outcomes but also seeks to minimize adverse side effects associated with conventional treatments. The increasing prevalence of HER2-positive tumors, coupled with a growing emphasis on individualized treatment plans, is driving demand for these therapeutics. As a result, pharmaceutical companies are intensifying research and development efforts, further shaping the landscape of the HER2 inhibitors market for the foreseeable future.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Technology Analysis
• Case Studies

Global HER2 Inhibitors Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Monotherapy
  • Single-Agent HER2 Inhibitors
  • Targeted HER2 Therapies
• Combination Therapy
  • HER2 Inhibitors Combined With Chemotherapy
  • HER2 Inhibitors Combined With Targeted Therapies
  • HER2 Inhibitors Combined With Hormonal Therapies

Global HER2 Inhibitors Market Size by Application & CAGR (2025-2032)

• Market Overview
• Squamous Cell Carcinoma
• Adenocarcinoma
• Large Cell Carcinoma
• Breast Cancer
• Other Applications

Global HER2 Inhibitors Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Other End Users

Global HER2 Inhibitors Market Size & CAGR (2025-2032)

• North America (Treatment, Application, End User)
  • US
  • Canada
• Europe (Treatment, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Genentech (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoffmann-La Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Symbio Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Puma Biotechnology (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipca Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations